LONG-TERM FOLLOW-UP OF OSIMERTINIB IN COMBINATION WITH PLATINUM AND PEMETREXED IN PATIENTS WITH PREVIOUSLY UNTREATED EGFR-MUTATED ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (THE OPAL STUDY): (NEJ032D)

LONG-TERM FOLLOW-UP OF OSIMERTINIB IN COMBINATION WITH PLATINUM AND PEMETREXED IN PATIENTS WITH PREVIOUSLY UNTREATED EGFR-MUTATED ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (THE OPAL STUDY): (NEJ032D) - NEJ032D

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060812

Enrollment

Registered

2026-03-04

Start date

2026-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

previously untreated EGFR-mutated advanced non-squamous NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All 67 patients (34 in the cisplatin group and 33 in the carboplatin group) enrolled in the phase II trial of osimertinib in combination with platinum-pemetrexed in patients with EGFR-mutated previously untreated advanced non-small cell Lung cancer (the OPAL study) conducted between March 1, 2019 and May 31, 2024. Trial: Phase II trial of osimertinib in combination with platinum-pemetrexed in patients with EGFR-mutated previously untreated advanced non-small cell Lung cancer (the OPAL study) 2. Individuals who did not express refusal to participate in this study, either themselves or through a representative who could act on their behalf and in their best interests.

Exclusion criteria

Exclusion criteria: Patients who withdrew their consent.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactMegumi Furuta

Hokkaido University Hospital Respiratory Medicine

furutamegumi@pop.med.hokudai.ac.jp011-706-5911

Outcome results